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Abstract
Epigenetics can be loosely defined as the study of cellular ‘‘traits’’ that influence biological phenotype in a fashion that is not
dependent on the underlying primary DNA sequence. One setting in which epigenetics is likely to have a profound
influence on biological phenotype is during intrauterine development. In this context there is a defined and critical window
during which balanced homeostasis is essential for normal fetal growth and development. We have carried out a detailed
structural and functional analysis of the placental epigenome at its maternal interface. Specifically, we performed genome
wide analysis of DNA methylation in samples of chorionic villus (CVS) and maternal blood cells (MBC) using both
commercially available and custom designed microarrays. We then compared these data with genome wide transcription
data for the same tissues. In addition to the discovery that CVS genomes are significantly more hypomethylated than their
MBC counterparts, we identified numerous tissue-specific differentially methylated regions (T-DMRs). We further discovered
that these T-DMRs are clustered spatially along the genome and are enriched for genes with tissue-specific biological
functions. We identified unique patterns of DNA methylation associated with distinct genomic structures such as gene
bodies, promoters and CpG islands and identified both direct and inverse relationships between DNA methylation levels
and gene expression levels in gene bodies and promoters respectively. Furthermore, we found that these relationships were
significantly associated with CpG content. We conclude that the early gestational placental DNA methylome is highly
organized and is significantly and globally associated with transcription. These data provide a unique insight into the
structural and regulatory characteristics of the placental epigenome at its maternal interface and will drive future analyses of
the role of placental dysfunction in gestational disease.
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Introduction
One area of genomics that is attracting intense interest is
epigenetics, which can be loosely defined as the study of cellular
‘‘traits’’ that influence biological phenotype in a fashion that is not
dependent on the underlying primary DNA sequence[1]. Of
particular significance is that epigenetic changes in genome
function can result in altered phenotypic states that are not only
sustained in the short term but may be heritable in a mitotic and
even meiotic fashion [2,3,4,5,6,7,8]. Gene environment interac-
tions are centrally involved in our susceptibility to disease and
these influences are likely to be mediated to a large degree via
epigenetic regulatory phenomena[9].
An important aspect of epigenetics is DNA methylation. There
is abundant evidence to suggest that DNA methylation is
intimately involved in the regulation of gene expression[10] and
that DNA methylation patterns can be altered as a component of
disease pathogenesis[11,12]. Evidence is also emerging to suggest
that DNA methylation is altered during development and by
environmental stress[6,13,14]. However, the mechanisms by
which these epigenetic influences are exerted are by no means
clear. There are many gaps in our knowledge regarding the
function of DNA methylation in various genomic contexts such as
promoters and gene bodies and the mechanisms by which DNA
methylation can influence gene expression.
One setting in which epigenetics is likely to have a profound
influence on biological phenotype is during intrauterine develop-
ment. In this context there is a defined and critical window during
which balanced homeostasis is essential for normal fetal growth
and development. Because of its central role in guiding fetal
development and acting as the gatekeeper of maternal environ-
mental exposure, the placenta responds to and is potentially
marked in an epigenetic context by environmental insults which
suggests that the placental epigenome might serve not only as a
record of in utero exposure but also as a mediator and/or
modulator of disease pathogenesis[15,16]. This is significant
because early gestational placental dysfunction has been implicat-
ed in a number of diseases including preeclampsia [17].
Furthermore, it is known that villus-derived apoptotic bodies are
a major source of the placentally-derived DNA and RNA species
in maternal plasma and it has been demonstrated that the
quantitative analysis of these molecules has significant utility for
the diagnosis and prognosis of both genetic and complex fetal
diseases [18,19,20,21].
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In light of the above, we have undertaken a comprehensive
analysis of cytosine methylation patterns in chorionic villus
samples (CVS) and gestational age-matched maternal blood cells
(MBCs) using two distinct microarray based methods. We provide
the first detailed analysis of the chorionic villus methylome at the
maternal interface in the context of both global gene expression
patterns and primary DNA sequence.
Materials and Methods
Tissue Handling and DNA Extraction
The collection of tissue samples was approved by the University of
Pittsburgh Institutional Review Board (PRO07070298). This project
includes no involvement of human subjects according to the federal
regulations [146.102(f)]. That is, no data was obtained through
intervention or interaction with the individual, nor was any
identifiable private information obtained. All samples used in this
study were discarded de-identified tissues. CVS samples were
obtained between gestational weeks 11 and 13 from the Magee
Womens Hospital Cytogenetic Screening Laboratory. All samples we
confirmed to have normal karyotypes using standard cytogenetic
techniques. Samples were dissected under a microscope and
separated from any decidual tissue or flecks of blood. The culture
media was removed and the tissue placed in 1.5–2.0 mL micro
centrifuge tubes before freezing at 280uC until DNA was extracted.
To extract DNA, one 5 mm stainless steel bead and 180 mL buffer
ATL (from Qiagen’s DNeasy Blood and Tissue kit) were added to
each CVS sample. The samples were placed in the TissueLyser
(Qiagen) Adaptor set 2624, and the TissueLyser was operated for 20
seconds at 30 Hz. The DNA was then purified using the DNeasy
Blood and Tissue kit as per the manufacturer’s protocol. MBCs were
obtained between gestational weeks 11 and 13 from the Magee
Women’s Hospital Prenatal Screening lab. DNA was extracted from
the MBC’s using a modified protocol previously described by
Iovannisci, et al., 2006 [22], using reagents from the MasturePure
DNA Purification Kit (Epincentre Technologies, Madison, WI, Cat.
No. MCD85201). Briefly, clotted blood (approximately 1 mL) was
mixed with an equal volume (1 mL) of 2X Tissue and Cell Lysis
Solution, votexed for 10 s and combined with 2 mL Tissue and Cell
Lysis Solution (MasturePure kit) containing 25 ng/mL proteinase K.
2 mL of MPC Protein Precipitation Reagent was added to the total
volume (4 mL) of the lysed sample and vortex vigorously for 10–
15 sec, after which samples were cooled on ice for $1 hour. Cell
debris were then pelleted by centrifugation (x2) for at least 30 min at
$2000 g and supernatants transferred to new 50 mL conical tubes.
DNA was precipitated in 2 volumes of isopropanol, purified by
phenol/chloroform extraction and resuspended in 50 mL DNAse/
RNAse free water.
Target DNA Preparation for Agilent Microarray Analysis
The Agilent data is MIAME compliant has been deposited in the
GEO database (http://www.ncbi.nlm.nih.gov/geo/) with the
accession number/series record GSE23835. Genomic DNA
samples (3 mg) were digested for two hours at 37uC with 50U
HpaII (New England Biolabs [NEB]) in 90 mL total reaction volume
using NEB buffer 4. A second aliquot of 50U, 1 mL of buffer 4, and
4 mL water were added and digestion continued overnight (total
reaction volume was 100 mL). Mock digestion controls were
included to monitor digestion efficiency. Following overnight
digestion, reactions were digested further with 5 uL (50U) of TspRI
(NEB) at 65uC for three hours. Reactions were then incubated
further with 75U (0.75 ml) Exonuclease III (NEB) and incubated at
30uC for 1 hour. Enzymatic activity was then nullified by heating at
70uC for 20 min after which 50U of RecJF (NEB) were added to
remove single stranded DNA. Reactions were incubated for 30 min
at 37uC and inactivated at 65uC for 20 min. Reactions were then
phenol-chloroform extracted and the DNA precipitated and
resuspended in 21.2 mL nuclease-free de-ionized water. Finally,
extracted genomic DNA was quantified and assessed for purity
using a NanoDrop ND-1000 UV-VIS Spectrophotometer.
CGH Target Labeling and Hybridization for Agilent
Microarrays
Experimental and reference DNA were labeled with Cy3-dUTP
and Cy5-dUTP respectively, and vice versa for dye-swaps, using a
BioPrime CGH Genomic Labeling kit per the manufacturer’s
protocol (Agilent). Hybridization was performed in a mix
containing 50 mL of human Cot-1, 52 mL of Agilent 10x blocking
agent, 260 mL of Agilent 2x HiRPM hybridization buffer, and
158 mL of the labeled DNA. The hybridization mix was heated to
95uC for 3 minutes, then incubated at 37uC for 30 minutes and
applied onto the active array area. Hybridization with gentle
agitation was carried out at 65uC for 40 hours. After hybridiza-
tion, the slides were washed in Oligo aCGH Wash Buffer 1 and
Oligo aCGH Wash Buffer 2, followed by acetonitrile and
Stabilization and Drying Solution (Agilent) per the manufacturer’s
protocol. The slides were scanned using an Agilent Scanner and
the data was analyzed using Agilent Feature Extraction software
8.1 (Agilent). Visualization and comparison of the datasets were
done with CGH-Analytics 3.2 (Agilent).
Infinium Microarray Analysis
The Infinium data is MIAME compliant has been deposited in
the GEO database (http://www.ncbi.nlm.nih.gov/geo/) with the
accession number/series record GSE23311. The HumanMethyla-
tion27 DNA Analysis BeadChip (Illumina) allows interrogation of
27,578 CpG sites based on the NCBI CCDS database (Genome
Build 36) and also targets the promoter regions of 110 miRNA
genes. Bisulphite conversion of DNA was carried out using the EZ
DNA MethylationTM Kit (Zymo Research Corp., CA) to convert
unmethylated cytosine nucleotides to uracil. Following denatur-
ation with 0.1N NaOH, converted DNA samples were amplified
by incubation at 37uC for 20 hours in a proprietary amplification
reaction mix. Amplified DNA was fragmented using vendor-
supplied reagents by incubation for one hour at 37uC. Fragmented
DNA sample was precipitated and resuspended in hybridization
buffer. Infinium BeadChips were cleaned and activated by
washing with ethanol, formamide and vendor supplied pre-
hybridization buffers. DNA samples are denatured, applied to
the Infinium arrays and hybridized 16–24 hours with rocking at
48uC. The BeadChip is placed into a flow-through chamber,
unhybridized and non-specifically hybridized DNA was washed
away and single base extension was performed on bound primers
with labeled nucleotides. Hybridized DNA sample was removed
by washing using proprietary buffers. Staining steps were
performed to attach florescent dyes to the labeled nucleotides
and the array surface sealed to protect the dyes from atmospheric
degradation. The final array was scanned using an Illumina
BeadArray Reader and the data analyzed using Bead Studio 2.0.
Determination of the methylation status of CpG sites
using Infinium Array Data
On an Infinium array, each targeted CpG site was interrogated
by 2 probes: probe A for unmethylation status, and probe B for
methylation status. The A probe signals and B probe signals were
normalized separately, using the cyclic loess algorithm (Wu). We
then computed the log ratio of probe B to probe A: log(B/A), as
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well as the beta value, which was defined as approximately B/
(A+B+100), assuming A, B$0. Both beta and log(B/A) can be used
as a measurement of the methylation level of a CpG site. In
particular, a CpG site was hypomethylated if the log (B/A) value of
that site was significantly lower than 0. It was hypermethylated if
log(B/A) is significantly higher than 0. Student’s t tests were used
to test if a CpG site was methylated in a group of samples, or if two
groups of samples had identical methylation rates at a given CpG
site. Empirical Bayesian method proposed in Smyth (2004) was
used to estimate the within group variance. P values were adjusted
using Benjamini and Hochberg’s method to control the false
discovery rate (FDR) at 5%.
Determination of methylation status at MspI sites using
custom Agilent E-Arrays
Each custom Agilent array was hybridized with an HpaII
digested sample (HpaII+) against the same sample without HpaII
digestion (HpaII2). If the CpG dinucleotide in an MspI site
recognition site was hypomethylated, the signal from the HpaII2
sample should be stronger than the signal from the corresponding
HpaII+ sample. If the CpG dinucleotide in an MspI site recognition
site was hypermethylated, the signal from the HpaII+ sample should
be the same as the signal from the corresponding HpaII2 sample.
We used the log signal ratio of HpaII2 to HpaII+ to measure the
hypomethylation level of the CpG in an MspI site: The MspI site
was hypomethylated if the value of log (HpaII2/HpaII+) for that
site was significantly above 0. Similarly, we determined that one
group of samples was more hypomethylated than another group at a
given MspI site if the log (HpaII2/HpaII+) of that site was
significantly higher in the first group than in the second group. The
statistical analysis of the Agilent E-Array data was similar to the
analysis of the Infinium Array data discussed above. The log
(HpaII2/HpaII+) signals were normalized using the cyclic loess
algorithm. Student’s t tests were used to test if a CpG site was
hypomethylated in a group of samples, or if two groups of samples
had identical hypomethylation status at a given CpG site. Empirical
Bayesian method was used to estimate the within group variance. P
values are adjusted with FDR controlled at 5%.
Determination of the Spatial Pattern of Hypomethylation
in Chromosomes 13, 18, and 21
We used the sliding window approach to visualize the
hypomethylation patterns of the MspI sites over the whole
chromosomes, and identify regions with significantly higher
methylation/hypomethylation levels. After identifying all MspI
sites that hypomethylated with FDR controlled at 5%, we
computed, 1) for both CVS and MBC samples, the moving
average of the hypomethylation rate for each MspI site, which was
defined as the percentage of hypomethyated MspI sites among the
50 MspI sites closest to that MspI site, and 2) the moving average
for the difference in hypothmethylation between CVS and MBC,
which was defined as, among the 50 MspI sites closest to that MspI
site, the difference in the number of hypomethylated sites between
CVS and MBC divided by 50. The moving averages were plotted
along the whole chromosomes for the visualization of the
hypomethylation pattern in CVS and MBC, and the difference
in hypomethylation between CVS and MBC.
To identify the regions with distinct hypomethylation pattern,
for each type of moving averages, we first ran simulations to get its
empirical distribution of the moving averages under the null
hypothesis that the methylation of the MspI sites is uniform over
the whole chromosomes, and that whether an MspI site is
methylated in CVS is totally independent of whether it is
methylated in MBC. Using the estimated empirical distribution,
we computed the p values for the moving average of hypomethy-
lation level or difference in hypomethylation level at each MspI
site. The p values were adjusted to control FDR at 5%. For each
type of moving averages, any two MspI sites with adjusted p values
#0.05 were merged provided there were fewer than 50 MspI sites
between them (recall that the moving average value at each MspI
site represents the average hypomethylation rate or the average
difference in hypomethylation rate over a 50-site long region). By
this approach we were able to identify, 1) the regions where the
MspI sites were significantly hypomethylated than other regions of
in the same chromosome, in either CVS or MBC, and 2) the
regions where the MspI sites were significantly more hypomethy-
lated in CVS vs. MBC, or significantly more hypomethylated in
MBC vs. CVS, than other regions of the same chromosome.
RNA Extraction from Tissues
Each tissue sample was combined with 1 ml Trizol (Invitrogen,
Carlsbad, CA) and a 5 mm steel bead and homogenized on a
TissueLyser (Qiagen, Valencia. CA) for 4 min at 30 Hz, rotating
the assembly halfway through the time. The volume was
transferred to a fresh tube and the cellular debris was pelleted
by centrifuging at 12000 g for 10 minutes at 4uC. The
homogenate was transferred to a fresh tube and incubated at
room temperature for 5 min. 200 ul of chloroform was added to
the sample, and then the samples were vortexed and allowed to
incubate at room temperature for 5 min. The samples were then
centrifuged at 12000 g for 15 min at 4uC. The aqueous phase was
transferred to a fresh tube, 500 ul isopropyl alcohol was added and
the samples were mixed and then incubated at room temperature
for 10 min. RNA was purified using Qiagen’s RNeasy Mini kit. In
brief, the samples were transferred to spin columns and
centrifuged at 8000 g for 15 seconds. The columns were washed
once with 700 ul buffer RW1 and twice with 500 ul RPE with
centrifugations for 15 seconds at 8000 g for each wash. The
columns were then placed in 1.5 ml centrifuge tubes, and the
RNA was eluted by adding 30 ul RNAse-free water and
centrifuging for 1 min at 8000 g.
Real Time Method
Each RNA sample was converted to cDNA using the High
Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA)
per the manufacturer’s protocol. TaqManGene expression assays
for the following genes: COL15A1 (Hs0026632_m1), GJA1
(Hs00748445_s1), LAMB1 (Hs01055971_m1), LUM (Hs0015
8940_m1), PITX2 (Hs00165626_m1), SLC16A4 (Hs00190794_m1),
TFPI2 (Hs00197918_m1) and VGLL3 (Hs01013372_m1), as well as
for the endogenous control GusB (Hs00939627_m1) were purchased
from Applied Biosystems. For each real time PCR reaction, 1 ul
cDNA, 1 ul gene expression assay, and 10 ul TaqMan gene expression
master mix were combined with water in a well on the reaction plate
for a total volume of 20 ul. Each reaction was run in triplicate, and
each sample was also run against the endogenous control on the same
reaction plate. This eliminated any differences in input DNA variation
and allowed the data to be read as a relative quantity. All samples were
normalized against one of the MBC samples. The real time PCR
reactions were read and analyzed using the 7900HT Sequence
Detection System (Applied Biosystems).
Analysis of the Association Between the Patterns of
Hypomethylation and the Pattern of Gene Expression
To analyze the relation between the methylation status of a
certain type of structural components of the genome, e.g., the
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promoters, and the expression levels of the genes corresponding to
those regions, we applied a nonparametric regression algorithm –
the cubic spline regression – to the data, with the gene expression
level as the dependent variable and the measurement of
methylation/hypomethylation, such as the average log(B/A) ratio
(for Infinium Array data) over each region, as the independent
variable. F tests were used to determine if the independent variable
was a significant predictor for the dependent variable, with the
trace of the smoother matrix used as the degrees of freedom of the
independent variable [23].
Results
We performed a genome wide analysis of DNA methylation in
first trimester CVS samples and gestational age matched MBCs.
Data were generated using two high-throughput approaches: the
Infinium ‘‘humanmethylation27’’ platform marketed by Illumina
and a custom Agilent-based platform. The former is targeted
towards 27,578 CpGs mostly contained within CpG islands and
well characterized promoter sequences that are spread throughout
the genome. Using this method we analyzed DNA samples
obtained from 12 CVS samples and 12 MBC samples. Using the
Agilent platform we carried out an unbiased high-throughput
analysis of DNA methylation on chromosomes 13, 18 and 21. This
approach was carried out on each of two pools of CVS and two
pools of MBC samples as previously described[24]. This custom
array contains 215,060 informative probes. Among them, 78,548
probes target 42,978 MspI/HpaII sites on chr18, with 35,570 sites
targeted by a matching pair of probes. Also, 46,675 probes target
25,878 MspI/HpaII sites in chr21, with 20,797 sites targeted by a
matching pair of probes. Furthermore, 89,837 probes target 49285
MspI/HpaII sites in chr13, with 40,552 sites targeted by a
matching pair of probes.
Of the 27,578 CpG sites targeted by the Infinium array, we
identified 563 that were hypermethylated in MBC and hypo-
methylated in CVS versus 155 sites that were hypomethylated in
MBC and hypermethylated in CVS. These can be considered to
be tissue-specific differentially methylated regions (T-DMRs).
Similar analysis of the custom/Agilent microarray data identified
6311 T-DMRs across chromosomes 13, 18 and 21[24]. A
significant number of these differentially methylated loci have
been verified and these data reported elsewhere[24].
CVS Genomes are Generally ‘‘More Hypomethylated’’
than MBC Genomes
We identified five fold more T-DMRs that were hypomethylated
in CVS versus MBC compared to those that were hypomethylated in
MBC versus CVS (Figure 1). This does not appear to be an artifact
since we observed the same phenomenon in both the Agilent and
Illumina data sets and each of these approaches relies upon
significantly different library preparation methods. Furthermore,
when we plotted the frequency of methylation at specific CpG sites in
MBCs using the Illumina data we found there to be a clear bimodal
distribution, with large numbers of CpG sites that are either
completely hypermethylated or completely hypomethylated
(Figure 2A). This bimodal pattern was also evident for a variety of
cell lines (Figure 2B) and primary ovarian tumor samples (Figure 2C).
These samples were used for comparison because they serve as
examples of both cultured and uncultured transformed cell tissue
types respectively. We chose neoplastic samples for this purpose
because of the previously suggested similarities between the molecular
phenotype of placental tissues and tumors [25]. Data from cell lines
were obtained directly from Illumina whereas the primary ovarian
tumor data were obtained in our own lab as part of a separate
experiment. The bimodal distribution was, however, not evident in
CVS genomes, which displayed significantly fewer fully hypermethy-
lated sites and significantlymore partiallymethylated sites (Figure 2D).
CVS vs. MBC T-DMRs Display Spatial Associations Within
Chromosomes 13, 18 and 21
We next asked whether there were significant differences in the
spatial location of T-DMRs that distinguish CVS and MBC
genomes. A primary goal of this analysis was to determine whether
T-DMRs are clustered together or dispersed randomly throughout
the genome. This required that our analysis focused on broad
differentially methylated genomic regions rather than individual
T-DMRs.
In order to identify broad regions of interest we employed the
‘‘sliding windows’’ approach described in Materials and Methods.
Using both the Infinium and Agilent data, we observed that the
distribution of broadly hypomethylated regions was very similar
for both CVS and MBC genomes. However, we found that T-
DMRs tend to cluster together in distinct chromosomal locations.
This phenomenon was apparent in both the Infinium (not shown)
and Agilent data sets, although it was more obvious in the latter
(Figure 3), in which the probes were more closely spaced, thereby
providing higher resolution. It is notable that regions dense in T-
DMRs were also those that encode the fewest numbers of
expressed sequence tags and mRNAs (compare the top and middle
panels of Figures 3A, 3B and 3C with the corresponding bottom
panel). This suggests that T-DMRs are more likely to be found
outside coding regions of the genome, a finding that is
corroborated by the data presented in Figure 4 (see below).
T-DMR Clusters are enriched for Developmentally
Significant Transcription Factors
We next explored the possibility that there was a functional
basis for the spatial clustering of T-DMRs. We approached this by
looking for correlations between these regions and their physical
relationship to known genes. Specifically we wanted to determine
whether regions where T-DMRs are clustered contained an over-
representation of genes involved in particular networks or GO
(gene ontology) functions. Sliding windows (see above) that showed
statistically significant differences between CVS and MBCs were
mapped to gene bodies and promoters. Specifically, we identified
regions that were a) hypomethylated in CVS versus MBC or b)
hypomethylated in MBC versus CVS.
We found that gene bodies and promoters that overlap broadly
hypomethylated regions in MBCs (relative to CVS) were highly
enriched for genes whose expressions are associated with the
regulation of gene expression. Specifically, we identified regions
hypomethylated in MBCs relative to CVS that overlapped with a
total of twenty-one gene bodies. Furthermore, the functions of only
sixteen of these have been previously characterized and a total of
thirteen (81%) were identified as encoding transcription factors.
These are listed in Table 1. Notably, a significant number of these
genes encode transcription factors that have functional significance
in the context of development and many of these are aberrantly
methylated at the DNA level in a variety of tumors[26,27,28,29,30].
To put this finding in context, we identified all the genes in Table 1
that include a gene ontology designation (GO) of ‘‘Development’’.
Of 20 GO annotated genes, only 9 have ‘‘development’’ in their
GO terms. These genes are identified in Table 1 by an asterisk.
Strikingly we discovered that there are a total of 786 genes on
chromosome 13, 18, and 21 that have GO annotations, and only 81
of them have ‘‘development’’ in their GO terms. We used a two
sided Fisher exact test against the null hypothesis that the proportion
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of genes related to development among the hypermethylated MBC
genes is the same as among all the other genes on chromosomes 13,
18 and 21. We discovered that there was a highly significant over-
representation of genes involved in development amongst spatially
clustered T-DMRs that are hypomethylated in MBCs versus CVS
(p= 0.00005574).
T-DMRs Are More Likely to be Located Outside CpG
Islands, Promoters and Gene Bodies
Given the bias towards less methylation in CVS versus MBC
genomes, we explored the relationship between T-DMRs and
their genomic locations in more detail. Because the Infinium array
generally only targets CpG sites within known CGIs and/or
promoter sequences we focused on data generated using the
custom Agilent oligonucleotide microarray that is targeted towards
every HpaII/MspI recognition sequence (CCGG) on chromo-
somes 13, 18 and 21 [31]. This platform has the advantage that
probes are not specifically targeted towards known promoters
and/or CGIs but instead are distributed in an unbiased fashion.
This allows the identification of methylated CpG sites and T-
DMRs that occur in other genomic regions such as gene bodies
and regions that are not known to encompass functional genes.
First, we compared the locations of T-DMRs where CVS was
hypomethylated relative to MBC with the locations of T-DMRs
where the methylation patterns of the two tissues do not show any
significant difference. We found that, using the Fisher’s exact test,
for all three chromosomes, these T-DMRs were significantly more
likely to be outside a gene body than inside a gene body
(Figure 4A). Furthermore, these T-DMRs were significantly more
likely to be outside a promoter than inside a promoter (Figure 4B)
and more likely to be outside than inside an exon (Figure 4D). In
addition, we found that, for all three chromosomes, T-DMRs
within which CVS was hypomethylated compared to MBC were
up to 10 times less likely to be inside a CGI (Figure 4C). This is
significant because it suggests that tissue specific methylation is
more likely to occur in regions where CpG sites are not required to
Figure 1. Scatter plot of genome-wide DNA methylation levels (Beta) of CVS and MBC genomes based on the Infinium data.
doi:10.1371/journal.pone.0014723.g001
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be strictly hypermethylated or hypomethylated. This can be
explained by the fact that CGIs are, by definition, regions where
CpGs are hypomethylated [32]. Therefore, they are unlikely to be
common sites of tissue specific methylation.
We also carried out the opposite analysis to that described
above. Specifically we compared the locations of T-DMRs in
which MBCs were hypomethylated (relative to CVS) with the
genomic regions in which the methylation patterns of the two
Figure 2. Histograms of genome wide methylation levels (Beta) in (A) 12 MBC samples (B) 12 cell lines (C) Primary ovarian tumors
and (D) 12 CVS samples based on the Illumina Infinium data. MBCs, cell lines and primary ovarian tumors display a bimodal distribution of
hyper and hypomethylation, CVS genomes have a dramatic reduction in the number of loci that are hypermethylated.
doi:10.1371/journal.pone.0014723.g002
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tissues did not show significant difference. We found that,
generally, these T-DMRs were less likely to exist inside CGIs
(Figure 4C) and exons (Figure 4D), and slightly more likely to exist
inside gene bodies and promoter regions (Figure 4A and B
respectively). However, we note that the results are much less
significant than those discussed above, mainly because we found
much fewer (812) sites where MBC was hypomethylated
compared to CVS than the 5,499 sites where CVS was
hypomethylated compared to MBC[24].
Hypomethylated Regions of the CVS and MBC Are More
Likely to be in CGIs, Promoters and Exons
We next considered CpGs that were hypomethylated in CVS
(relative to the rest of the CVS genome) and/or hypomethy-
lated in MBCs (relative to the rest of the MBC genome). Those
sites in gene bodies showed no clear pattern in CVS whereas
such sites in MBC were slightly more likely to be outside (than
inside) gene bodies (Figure 5A). The pattern for promoters was
very clear. Using the Fisher’s exact test, we found that
hypomethylated sites were much more likely to be inside
promoters than other sites. This was true for both CVS and
MBC (Figure 5B). The patterns for CGIs and exons were
similar to the pattern for promoters. Specifically, hypomethy-
lated sites were much more like to be inside CGIs or exons, as
oppose to outside CGIs or inside introns, than the non-
hypomethylated sites. This was true for both CVS and MBC
(Figure 5C and D). We also found that sites hypomethylated in
MBC were even more likely than in CVS to be inside (as
oppose to outside) a promoter or CGI, which partly explains
why sites more hypomethylated in CVS than in MBC were
more like to be outside of CGI and promoter than sites more
hypomethylated in MBC than in CVS.
Figure 4. Distributions of differentially methylated and non-differentially methylated MspI sites in various structural components
of the genome based on custom Agilent microarray data. OT: MspI sites not differentially methylated in CVS vs. MBC. CM: MspI sites more
hypomethylated in CVS than in MBC. MC: MspI sites more hypomethylated in MBC than in CVS. Data are presented for each chromosome (13, 18, 21),
and each type of MspI sites (OT, CM, MC), as the proportions of sites that are located inside (A) gene bodies (B) promoter regions (C) CGIs and (D)
exons.
doi:10.1371/journal.pone.0014723.g004
Figure 3. Top: Moving average of the hypomethylation levels of the MspI sites levels in CVS (solid line) and MBC (dashed line).
Middle: Moving average of the difference in the hypomethylation levels of the MspI sites between CVS and MBC. The short dense vertical lines above
the X axis (appearing as a solid horizontal line) in both the top and bottom panels represent locations of the MspI sites in each chromosome. Bottom:
Histogram of the EST and mRNAs aligned to the chromosome generated using NCBI genome Map Viewer. (A) Chromosome 13. (B) Chromosome 18.
(C) Chromosome 21.
doi:10.1371/journal.pone.0014723.g003
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Pathway Analysis Reveals that T-DMRs are Enriched for
Distinct Functional Groups
To further explore the relationship between T-DMRs and gene
function we analyzed the Illumina data using Ingenuity Pathways
Analysis (IPA) software. Specifically, we performed a gene
ontology analysis of T-DMRs where CpGs are hypomethylated
in MBC versus CVS and vice versa. We found that T-DMRs
hypomethylated in MBC versus CVS were significantly biased
towards genes that are involved in tissue specific leukocyte
function. For example, the top networks identified in IPA were
heavily biased towards immune function. These IPA-designated
enriched networks are listed in Table S1. Similarly, the top IPA-
identified biological functions (Figure 6A and Table S2) were
‘‘Antigen Presentation’’, ‘‘Cell Mediated Immune Response’’ and
‘‘Humoral Immune Response’’. These findings suggest that T-
DMRs that are hypomethylated in the promoters of the MBC
genome (compared to CVS) have strong functional significance.
This apparent relationship between tissue function and T-DMR
profile was not so clear when we performed the same analysis on
T-DMRs that are hypomethylated in the promoters of the CVS
genome (compared to MBC). It should be noted, however, that we
identified more than three times as many high scoring networks
amongst the hypomethylated CVS T-DMRs than their hypo-
methylated MBC counterparts. This may reflect both the broad
range of biological functions performed in/by CVS and the fact
that it contains multiple distinct cell types. These factors likely
conspire to complicate the task of identifying distinct pathways and
biological functions. IPA-designated enriched networks for these
data are listed in Table S3. High scoring IPA-designated biological
functions (Figure 6B and Table S4) include ‘‘Gene Expression’’,
‘‘Cancer’’ and Organismal Development’’.
Functional Groups Enriched in T-DMRs are also Enriched
in Differentially Transcribed Genes
Given the potential for DNA methylation patterns to be
intimately associated with gene expression, we sought to determine
whether T-DMRs identified in the Illumina data were also present
as tissue specific differentially transcribed genes (TDTs). Thus, we
analyzed Affymetrix gene expression microarray data to identify
CVS- and MBC-specific TDTs and then analyzed these data using
IPA. A sub-set of TDTs was validated using quantitative real time
PCR. These data, which demonstrate tissue specific gene
expression in CVS, are presented in Figure 7. We found very
little overlap between T-DMRs and TDTs. Specifically, we found
only 6 genes (of a total of 207) that were both more highly
expressed AND contained CpGs that were hypomethylated in
MBC versus CVS. These were CD48, CD52, CMTM2, CST7,
LYZ and NFE2. No overlap was found between genes that were
more highly expressed AND hypermethylated in MBC versus
CVS. Similarly, we found 14 genes (of a total of 643) that were
both more highly expressed AND hypomethylated in CVS versus
MBC. These were ANGPT2, CDH1, COL3A1, CRIM1, CSH2,
ENPEP, GCM1, H19, INSL4, KRT8, LGALS14, PGM3,
SLC16A4 and STS. No overlap was found between genes that
were more highly expressed AND hypermethylated in CVS versus
MBC. The fact that such minimal overlap was seen between data
sets was not the result of minimal overlap between the DNA
methylation and gene expression array platforms, which contain
11,337 common genes. It may, however, be a consequence of our
rather stringent approach to selecting TDTs (see Materials and
Methods), which resulted in a relatively short list of candidate
genes. However, when we compared pathway analysis data
obtained using IPA for genes that were both more highly
Table 1. Genes Identified Within Broadly Hypomethylated Regions of MBC Versus CVS.
Gene Names Symbol Type Active Location
Chromosome 18 open reading frame 18 C18ORF18 Other Unknown
Caudal type homeobox 2 CDX2* Transcription regulator Nucleus
Collagen, type IV, alpha 2 COL4A2 Other Extracellular Space
Deleted in lymphocytic leukemia 2 (non-protein coding) DLEU2 Other Unknown
GATA binding protein 6 GATA6* Transcription regulator Nucleus
GS homeobox 1 GSX1 Transcription regulator Nucleus
Neurocanthocytosis NA Other Unknown
Neurocanthocytosis NA Other Unknown
One cut homeobox 2 ONECUT2* Transcription regulator Nucleus
Protocadherin 17 PCDH17 Other Unknown
Pancreatic and duodenal homeobox 1 PDX1 Transcription regulator Nucleus
POU class 4 homeobox 1 POU4F1 Transcription regulator Nucleus
RAB20, member RAS oncogene family RAB20 Enzyme Cytoplasm
Receptor-interacting serine-threonine kinase 4 RIPK4 Kinase Nucleus
Ring finger protein 219 RNF219 Other Unknown
Sal-like 3 (Drosophila) SALL3* Other Nucleus
Single-minded homolog 2 (Drosophila) SIM2 Transcription regulator Nucleus
SRY (sex determining region Y)-box 1 SOX1* Transcription regulator Nucleus
SRY (sex determining region Y)-box 21 SOX21 Transcription regulator Nucleus
Zinc finger protein 161 homolog (mouse) ZFP161 Other Nucleus
Zic family member 2 (odd-paired homolog, Drosophila) ZIC2* Transcription regulator Nucleus
doi:10.1371/journal.pone.0014723.t001
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expressed AND hypermethylated in MBC versus CVS, we found a
striking overlap in enriched networks and biological functions,
despite the minimal overlap in specific genes. As shown in Table
S5, the most significant IPA-designated networks identified
amongst genes whose expressions were elevated in MBC relative
to CVS overlap closely with those identified among genes
hypomethylated in MBC versus CVS (Table S1). Similarly
overlapping were the IPA-designated biological functions, which
can be seen by comparison between Tables S2 and S6. Such
overlap was present but not so obvious when networks (Table S7)
and biological pathways (Table S8) derived from lists of genes
whose expressions were elevated AND hypomethylated in CVS
versus MBC were observed (compare to Tables S3 and S4
respectively).
T-DMRs are Correlated with Levels of Gene Transcription
To explore the global relationship between gene expression and
DNA methylation patterns we downloaded gene expression
microarray data obtained using mRNA derived from CVS tissue
[33] and MBCs from NCBI Gene Expression Omnibus (GEO)
(accession number GSE14771). Notably, and in keeping with the
observation that CVS genomes are more hypomethylated than
MBC genomes, we found there to be twice as many mRNAs over-
expressed in CVS versus MBC than vice versa (Table S9). We
compared the CVS mRNA transcription profile derived from
these Affymetrix data with the DNA methylation profile derived
from the Infinium data and found a significant negative
correlation between the degree of promoter methylation and the
expression level of the corresponding gene (Figure 8A). For these
purposes, the promoter region was defined as 1500 upstream to
1500 downstream of the transcriptional start site (TSS), as in
Rakyan et al (2008) [34]. All CpG sites targeted by the Illumina
array were located within this range. Specifically, we estimated
expression levels and promoter methylation rate for 13,847 genes.
The expression level of a gene was obtained by averaging the log
signal intensity of the probe sets targeting that gene over the 8
normal CVS samples. The promoter methylation rate was
estimated by averaging the log ratio of B probe to A probe–
log(B/A)–over the 12 CVS samples. The log(B/A) is an indicator
of the level of methylation: the higher the methylation level, the
higher the value of log(B/A). Using the Infinium methylation data,
we found that the correlation between the expression level and
log(B/A) is 20.35 (p value of t test,2.2610216). Moreover, the
relationship between the expression level and methylation level is
nonlinear. We ran a nonparametric regression and found that,
when the methylation level is less than 50% (log B/A,0), there is
a linear negative relationship between methylation and expression.
When methylation level is greater than 50% (logB/A.0) however,
methylation and expression is uncorrelated. In Figure 8A, the solid
line shows the relationship between gene expression levels and
Figure 5. Distributions of hypomethylated and non-hypomethylated MspI sites in CVS andMBC tissues in various types of genomic
regions based on custom Agilent microarray data. CVO: MspI sites not hypomethylated in CVS. CVH: MspI sites hypomethylated in CVS. MBO:
MspI sites not hypomethylated in MBC. MBH: MspI sites hypomethylated in MBC. Data are presented for each chromosome (13, 18, 21) and each type
of MspI site (CVO, CVH, MBO, MBH), as the proportion that are located inside (A) gene bodies (B) promoter regions (C) CGIs (D) exons.
doi:10.1371/journal.pone.0014723.g005
Epigenetics of the Placenta
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e14723
DNA methylation in CVS based on the Infinium methylation
data. The above trends were similarly present in the relationship
between DNA methylation and mRNA transcription in MBCs
(Figure 8B), though not as strong as in CVS.
To gain further insight into the relationship between gene
expression and methylation, we compared the CVS gene
expression profile with the DNA methylation profile for the 3
chromosomes 13, 18, and 21 based on the custom Agilent arrays.
We estimated the hypomethylation level of each MspI/HpaII site
in the three chromosomes by determining the log ratio of the
signal of the control samples to the signal of samples digested with
HpaII: log(HpaII2/HpaII+). Unlike the Infinium arrays, which
targeted only CpG sites inside the promoter regions, the custom
Agilent arrays targeted CpG sites at high density all over the three
chromosomes. This allowed us to determine how the methylation
patterns of the different structural components of the genome were
related to the gene expression profile.
For genes in chromosomes 13, 18, and 21, we found a positive
correlation of 0.194 (p value of the t test = 2.126610206) between the
hypomethylation level of their promoter regions and their expression
level (Figure 8C), where the promoter region was defined as 1500
upstream and 1000 downstream of the TSS. This finding agrees with
the previous analysis of the relationship between DNA methylation
and gene expression using the Illumina data. In Figure 8C, the solid
line shows how the expression level relates to the hypomethylation
level of the promoter regions chromosomes 13, 18, and 21.
Furthermore, we found a negative correlation of 20.111 (p value
of t test = 0.0018) between the hypomethylation level of the gene
body and the expression level, where ‘‘gene body’’ includes both
exons and introns (Figure 8D). The relation between hypomethyla-
tion and expression is nonlinear. When the genes are moderately or
highly hypomethylated (log(HpaII2/HpaII+).0.03), hypomethyla-
tion level and expression level are uncorrelated. When the genes are
only weakly or not hypomethylated (log(HpaII2/HpaII+),0.03),
there is a significant negative correlation between hypomethylation
level and expression. In Figure 8D, the solid line shows how the
expression level relates to the hypomethylation level of the gene
bodies in chromosomes 13, 18, and 21. This relationship is more
pronounced when gene bodies containing CGIs are removed from
the analysis (Figure 8E). Finally, it can be seen in Figure 8F that
among the MspI sites inside gene bodies, the hypomethylation levels
are higher for those inside CGIs, compared to those outside CGIs.
The Relationship Between DNA Methylation Levels and
Gene Expression are Dependent on Promoter CpG
Frequency
Figure 9 illustrates the relationships between promoter meth-
ylation and expression in CVS samples in the context of promoter
CpG frequency. As shown in Figure 9A the genes form two
clusters based on their promoter CpG frequency (observed CpG/
expected CpG) and genes with high CpG frequency promoters
tend to be more highly expressed. Figure 9B shows that the genes
also form two clusters based on their promoter CpG frequency
with respect to promoter methylation levels. Genes in the low CpG
frequency cluster tend to be hypermethylated, whereas the genes
in the high CpG frequency cluster tend to be hypomethylated.
Figures 9C and D show the nonlinear relationship between
expression and methylation in each of the two clusters identified in
Figure 9B. When CpG frequency is #0.4 (Figure 9C), the
relationship between methylation and expression shows no clear
Figure 6. Biological Functions of genes hypomethylated in MBC versus CVS (A) and vice versa (B) Identified Using Ingenuity
Pathways Analysis Software.
doi:10.1371/journal.pone.0014723.g006
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pattern, whereas when CpG frequency is . 0.4, for genes with
hypomethylated promoters, gene expression is positively correlat-
ed with hypomethylation level, or equivalently, negatively
correlated with methylation level (Figure 9D). The data presented
in Figure 9D are consistent with our previous observations of the
relationship between promoter methylation and gene expression
(without considering CpG frequency) based on data obtained
using both the Agilent array and Infinium arrays (Figure 8A,B,C).
That is, promoter methylation level is negatively correlated with
gene expression, especially for genes with relatively hypomethy-
lated promoter.
Discussion
We present a comprehensive epigenetic analysis of the placental
chorionic villus (CVS) and gestational age matched maternal
blood cells (MBC) at the level of DNA methylation. In addition to
providing detailed insight into the structure and organization of
the CVS and MBC methylomes in the context of promoters, CpG
islands and gene bodies, we present novel findings relating the
methylation levels of these genetic elements to gene expression
levels, biological function and primary DNA sequence.
One fundamental difference between the CVS and MBC
genomes is the bias towards a hypomethylated state in the former.
Related to this is that fact that, unlike the differentiated adult tissues
and tumor samples we investigated, CVS genomes do not have a
bimodal distribution of hyper- and hypomethylated sites. We found
these to be global phenomena, for which the biological basis is
unclear. These observations may however be related to the fact that
very early gestational trophoblast stem cells display a hypomethy-
lated genomic state that is consistent with a semi-pluripotent
phenotype[35]. This is supported by the fact that trophoblast
lineages are thought to retain pluripotency for some time after
implantation[36] and the observation that relative hypomethylation
in CVS versus MBC in the first trimester is lost by the third
trimester[37]. The relative hypomethylation of CVS versus MBC
may also be related to the highly proliferative and invasive nature of
this tissue and its requirement for a highly active and complex
transcriptional state. Interestingly, Papageorgiou et al., (2009)[37]
recently reported similar findings using an immunoprecipitation-
based approach although this was not as pronounced as in our data
and was not the case for all chromosomes.
The spatial association of broadly hypomethylated regions
observed in CVS and MBC genomes is intriguing. It is conceivable
that such differentially methylated regions play a role in the
regulation of expression of functionally related genes such as those
identified in Table 1. The fact that some of these genes are
aberrantly methylated at the DNA level in a variety of tumors[37]
is notable given the previously noted link between the ‘‘molecular
phenotype’’ of tumors and early mammalian development[25].
The discovery that T-DMRs are more likely to be located outside
promoters and gene bodies suggests that tissue specific differences in
Figure 7. Real time PCR analysis was performed using total RNA samples fromMBC (n=6) and CVS (n=6) to detect transcript levels
encoded by the following genes: COL15A1, GJA1, LAMB1, LUM, PITX2, SLC16A4, TFPI2 and VGLL3. Each reaction was run in triplicate
against an endogenous control (GUSB) and normalized against one of the MBC samples. The median logRQ was plotted for each gene.
doi:10.1371/journal.pone.0014723.g007
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DNA methylation are not limited to regions of the genome that have
traditionally been associated with tissue specific gene expression. This
raises a number of possibilities. For example, it may be that genomic
regions outside gene bodies and promoters are important for the
regulation of tissue-specific gene expression. It is also possible that
tissue specific differences in DNA methylation are of minimal
functional significance in the context of tissue specific gene expression.
The observation that T-DMRs are highly unlikely to be found in
CpG islands can be explained by the fact that CpG islands are, by
definition, regions where CpGs are hypomethylated[19]. Therefore,
they are unlikely to be common sites of tissue specific methylation.
The fact that hypomethylated regions of the CVS and MBC
genomes are highly likely to be located inside (compared to
outside) promoters and CpG islands (Figure 4B and 4C) is
consistent with previous analyses in other tissues[34]. It is
interesting, however, that this phenomenon is also apparent in
exons, particularly given the fact that we also found a positive
correlation between gene body methylation and gene expression.
It would be interesting therefore to specifically identify those exons
that do NOT appear to be hypomethylated and determine if these
are strongly associated with gene expression.
The notion that there is an organized functional relationship
between DNA methylation and tissue-specific biological function is
supported by the data presented in Figure 6A in which we identified a
clear correlation between tissue specific methylation and cell type
specific biological function in MBCs. The fact that this relationship
was less clear for CVS is likely to be related to the fact that CVS is
both more hypomethylated and also more transcriptionally active.
Similarly, it is interesting that, despite almost no overlap in gene
specific DNA methylation and transcription, we found ‘‘functional’’
overlap identified by IPA analysis (Table S1). This suggests that DNA
methylation patterns in CVS and MBC may provide a permissive
framework within which the potential for gene-specific expression is
enabled but not necessarily actualized at the time of sample
collection. Such a relationship might further explain why we found
it more difficult to identify a clear correlation between tissue specific
methylation and cell type specific biological function in CVS.
Specifically, it may be that the dynamic complexity of CVS
transcription throughout early gestation requires a broadly hypo-
methylated permissive DNA methylome to enable appropriate gene
expression.
Our discovery that the DNA methylome is broadly related to
gene expression patterns is consistent with previous observations in
other tissues but novel in the context of global analysis in
CVS[10,38,39]. Unlike previous studies, however, we found that
the negative correlation between the degree of promoter methyl-
ation and the expression level of the corresponding gene was non-
linear, only being evident when the methylation level is less than
50%. This was true for both CVS and MBC. There was also a
negative correlation between the hypomethylation level of the gene
Figure 8. Genome wide relationship between gene expression and promoter methylation for (A) CVS and (B) MBC. The X axis is the
average log ratio of signal B to signal A of probes targeting each probe on the Infinium array. Negative values indicate hypomethylation and positive
values hypermethylation. The Y axis is the log2 gene expression level. The solid line represents the fitted values of the nonparametric regression of
the gene expression level against the methylation level. The two dashed vertical lines mark clusters of hypomethylated and hypermethylated genes.
C–E. Relation between CVS gene expression and hypomethylation level of various types of genomic regions in chromosomes 13, 18, and 21. The X
axis is the hypomethylation level of various genomic regions, measured as the log ratio of the signals from the control samples to the signal of the
HapII digested samples averaged over the probes targeting the same genomic region. The Y axis is the log2 gene expression level. The solid line
represents the fitted values of the nonparametric regression of the gene expression level against the hypomethylation level of various types of
genomic regions. (C) Relationship between CVS gene expression and promoter hypomethylation in chromosomes 13, 18, and 21. (D) Relationship
between CVS gene expression and gene body hypomethylation in chromosomes 13, 18, and 21. (E) Relationship between CVS gene expression and
the non-CGI gene body hypomethylation in Chromosomes 13, 18, and 21. (F) Box plots of the hypomethylation level of the MspI sites inside gene
bodies in Chromosomes 13, 18, and 21, as determined by custom Agilent arrays. Left: MspI sites inside gene bodies and CGIs. Right: MspI sites inside
gene bodies but outside CGIs.
doi:10.1371/journal.pone.0014723.g008
Epigenetics of the Placenta
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e14723
body and expression level and again we found this to be nonlinear.
Specifically, when the gene bodies are moderately or highly
hypomethylated, hypomethylation level and expression level are
uncorrelated, whereas when the gene bodies are only weakly or not
hypomethylated there is a significant negative correlation between
hypomethylation level and expression. These data extend previous
observations by providing preliminary insight into the subtleties of
the relationship between DNA methylation and gene expression.
The finding that CVS and MBC promoters are naturally
clustered into two groups according to CpG frequency is highly
significant. Specifically, for the promoters in the high CpG
frequency group, methylation level is negatively correlated to the
gene expression level, especially for the hypomethylated promot-
ers, whereas no clear relation between methylation and expression
could be derived for the promoters in the low CpG frequency.
This contrasts previous observations by Beck et al., (2008) who
found that the relationship between DNA methylation and gene
expression was largely independent of CpG frequency[38]. It may
be that these differences can be explained by the use of different
molecular approaches. However, it is important that these
observations are further explored.
In summary, we have performed the first comprehensive
structural and functional analysis of the early gestational human
placental epigenome at its maternal interface. Our data provide
detailed insight into global DNA methylation patterns and their
relationship to gene expression in the human chorionic villi. Our
data also provide a foundation for the molecular characterization
of gestational diseases such as preeclampsia, which have a
placental component, and the development of non-invasive
biomarkers for their minimally invasive detection and manage-
ment.
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Table S1 IPA biological network analysis of genes hypomethy-
lated in MBC versus CVS.
Found at: doi:10.1371/journal.pone.0014723.s001 (0.04 MB
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Table S2 IPA biological pathway analysis of genes hypomethy-
lated in MBC versus CVS.
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Figure 9. Relationships between promoter methylation and expression in CVS samples in the context of promoter CpG frequency
(A) X axis: CpG frequency (defined as the observed CpG/expected CpG) of the promoter region of each gene. Y axis: Log2 gene
expression levels in CVS (B) X axis: CpG frequency of the promoter region of each gene. Y axis: Log ratio of signal B to signal A averaged over probes
targeting the promoter region of each gene in CVS. C–D: Relationship between transcription level and promoter region methylation level. X axis: Log
ratio of signal B to signal A averaged over probes targeting the promoter region of each gene. Y axis: CpG frequency of the promoter region of each
gene. Solid lines represent the fitted values of the nonparametric regression of the transcription level against methylation level. (C) Plot of genes
whose promoter regions have a CpG frequency,0.4. (D) Plot of genes whose promoter regions have a CpG frequency.0.4.
doi:10.1371/journal.pone.0014723.g009
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